

AMENDMENTS TO THE CLAIMS

Please amend the claims as follows:

1. (Currently Amended) A method of screening for a therapeutic agent for pancreatic cancer, wherein the method comprises the steps of:

(a) contacting a test substance, or a salt thereof, with a purified serine/threonine kinase Pim-1 polypeptide or a partial peptide thereof having Pim-1 phosphorylation activity, ~~or a salt thereof~~;

(b) detecting the phosphorylation activity of the purified serine/threonine kinase Pim-1 polypeptide; and

(c) identifying a test substance that inhibits the phosphorylation activity of the purified serine/threonine kinase Pim-1 polypeptide, wherein a test substance that inhibits the phosphorylation activity of the serine/threonine kinase Pim-1 polypeptide is a therapeutic agent for pancreatic cancer.

10. (Currently Amended) A method of screening for an apoptosis-inducing agent for pancreatic cancer, wherein the method comprises the steps of:

(a) contacting a test substance, or a salt thereof, with a purified serine/threonine kinase Pim-1 polypeptide or a partial peptide thereof having Pim-1 phosphorylation activity, ~~or a salt thereof~~;

(b) detecting the phosphorylation activity of the purified serine/threonine kinase Pim-1 polypeptide; and

(c) identifying a test substance that inhibits the phosphorylation activity of the purified serine/threonine kinase Pim-1 polypeptide, wherein a test substance that inhibits the phosphorylation activity of the serine/threonine kinase Pim-1 polypeptide is an apoptosis-inducing agent for pancreatic cancer solid tumor.

17. (Currently Amended) A method of screening for an anticancer agent potentiator for pancreatic cancer, wherein the method comprises the steps of:

(a) contacting a test substance, or a salt thereof, with a purified serine/threonine kinase Pim-1 polypeptide or a partial peptide thereof having Pim-1 phosphorylation activity, ~~or a salt thereof~~;

(b) detecting the phosphorylation activity of the purified serine/threonine kinase Pim-1 polypeptide; and

(c) identifying a test substance that inhibits the phosphorylation activity of the purified serine/threonine kinase Pim-1 polypeptide, wherein a test substance that inhibits the phosphorylation activity of the serine/threonine kinase Pim-1 polypeptide is an anticancer agent potentiator for pancreatic cancer.

AMENDMENT TO THE SPECIFICATION

Please amend the specification in Example 14 at page 14, paragraph [0180] of the published application as follows:

“Silencer siRNA Construction Kit (Ambion) was used to produce SiRNA comprising a polynucleotide comprising the nucleotide sequence of SEQ ID No: 9 and a polynucleotide comprising the nucleotide sequence of SEQ ID No: 10 [9];...”

The duplicate reference to ‘SEQ ID No: 9’ in the sentence indicated above is an obvious error. It is clear from the remainder of the specification that the sentence indicated above should refer to both SEQ ID No: 9 and SEQ ID No: 10. See, for example, page 10, paragraph [0131] of the published application, which states:

“Double-stranded RNAs corresponding to the polynucleotides comprising the nucleotide sequence of SEQ ID No:2 include, for example: double stranded RNAs that comprise a polynucleotide comprising the sequence of SEQ ID No:9 (5'-.....-3') and a polynucleotide comprising the sequence of SEQ ID No:10 (5'-.....-3');.....” (sequences omitted).